Advertisement

Current Hematologic Malignancy Reports

, Volume 13, Issue 3, pp 183–190 | Cite as

Splanchnic Vein Thrombosis in the Myeloproliferative Neoplasms

  • Imo J. Akpan
  • Brady Lee Stein
Myeloproliferative Neoplasms (B Stein, Section Editor)
  • 215 Downloads
Part of the following topical collections:
  1. Topical Collection on Myeloproliferative Neoplasms

Abstract

Purpose of Review

To review the epidemiology, diagnostic challenges, pathogenesis, and treatment strategies for patients with myeloproliferative neoplasm-associated splanchnic vein thrombosis.

Recent Findings

The epidemiology of myeloproliferative neoplasm-associated splanchnic vein thrombosis (MPN-SVT) has been well characterized. While typical MPN-associated thrombosis affects older patients and involves the arterial circulation, MPN-SVT mostly impacts younger women. An association with JAK2 V617F is well-known; recent studies have demonstrated only a weak association with CALR mutations. JAK inhibition may represent a novel treatment strategy, complementing anticoagulation, and management of portal hypertension.

Summary

While the epidemiology has been well characterized, more work is needed to identify novel contributors to disease pathogenesis, beyond the JAK2 V617F mutation itself, and endothelial compromise. Testing for MPN mutations in the setting of non-cirrhotic SVT is commonplace; JAK2 V617F is the most likely to be identified. Testing for CALR or MPL mutations requires clinical judgement, though not unreasonable. The mainstay of therapy is indefinite anticoagulation; the role of direct oral anticoagulants is unclear. JAK inhibition may play a role in addressing associated splenomegaly and portal hypertension.

Keywords

Splanchnic vein thrombosis JAK2 V617F mutation Myeloproliferative neoplasm Polycythemia vera 

Notes

Compliance with Ethical Standards

Conflict of Interest

Brady Stein reports other from Incyte Corporation, outside the submitted work. Imo J. Akpan has no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372–5.PubMedGoogle Scholar
  2. 2.
    Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2012;2012:571–81.  https://doi.org/10.1182/asheducation-2012.1.571.PubMedGoogle Scholar
  3. 3.
    Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778–82.  https://doi.org/10.1182/blood-2009-08-238956.CrossRefPubMedGoogle Scholar
  4. 4.
    Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33.  https://doi.org/10.1056/NEJMoa1208500.CrossRefPubMedGoogle Scholar
  5. 5.
    Gugliotta L, Iurlo A, Gugliotta G, Tieghi A, Specchia G, Gaidano G, et al. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2016;46:18–25.  https://doi.org/10.1016/j.leukres.2016.04.004.CrossRefPubMedGoogle Scholar
  6. 6.
    Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–51.  https://doi.org/10.1182/blood-2013-11-539098.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552–5.  https://doi.org/10.1182/blood-2013-11-538983.CrossRefPubMedGoogle Scholar
  8. 8.
    •• Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–21.  https://doi.org/10.1056/NEJMoa1701719. Large case control study shows that clonal hematopoiesis of indeterminate potential (CHIP) mutations such as DNMT3A , TET2 , ASXL1 , and JAK2 is associated with increased risk of coronary artery disease mediated by inflammation CrossRefPubMedGoogle Scholar
  9. 9.
    • Taniguchi Y, Tanaka H, Luis EJ, Sakai K, Kumode T, Sano K, et al. Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms. Int J Hematol. 2017;106(5):691–703.  https://doi.org/10.1007/s12185-017-2302-5. Study shows that MPN patients with thrombotic events have higher plasma levels of procoagulant microparticle (MP) expressing tissue factor (TF) and suggests that MP expressing TF may potentially serve as another risk factor for thrombotic events in MPN in the future CrossRefPubMedGoogle Scholar
  10. 10.
    Thatipelli MR, McBane RD, Hodge DO, Wysokinski WE. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol. 2010;8(2):200–5.  https://doi.org/10.1016/j.cgh.2009.09.019.CrossRefPubMedGoogle Scholar
  11. 11.
    •• Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Bang SM, Senzolo M, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med. 2015;175(9):1474–80.  https://doi.org/10.1001/jamainternmed.2015.3184. Large prospective study of 604 consecutive patients with SVT which shows that these patients have an increased long-term risk of recurrent thrombosis. That risk is even higher in patients with solid cancer, myeloproliferative neoplasms, and unprovoked SVT CrossRefPubMedGoogle Scholar
  12. 12.
    Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120(25):4921–8.  https://doi.org/10.1182/blood-2011-09-376517.CrossRefPubMedGoogle Scholar
  13. 13.
    Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013;54(9):1989–95.  https://doi.org/10.3109/10428194.2012.759656.CrossRefPubMedGoogle Scholar
  14. 14.
    Stein BL, Rademaker A, Spivak JL, Moliterno AR. Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thrombosis. 2011;2011:874146.  https://doi.org/10.1155/2011/874146.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–81.  https://doi.org/10.1038/leu.2013.163.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    •• Hultcrantz M, Bjorkholm M, Dickman PW, Landgren O, Derolf AR, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168:317–25.  https://doi.org/10.7326/M17-0028. Large study in Sweden of 9429 patients with MPNs and 35,820 matched control shows that patients with MPN have a higher rate of thrombosis compared to the control participants across all age groups. The thrombotic rate is much higher shortly after diagnosis. This study includes the hazard ratios for both arterial and venous thrombosis.CrossRefPubMedGoogle Scholar
  17. 17.
    Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, et al. Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. Clin Lymphoma Myeloma Leuk. 2015;15(1):e1–5.  https://doi.org/10.1016/j.clml.2014.04.004.CrossRefPubMedGoogle Scholar
  18. 18.
    Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111(10):4922–9.  https://doi.org/10.1182/blood-2007-11-125328.CrossRefPubMedGoogle Scholar
  19. 19.
    Karakose S, Oruc N, Zengin M, Akarca US, Ersoz G. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis. Turk J Gastroenterol. 2015;26(1):42–8.  https://doi.org/10.5152/tjg.2015.5738.CrossRefPubMedGoogle Scholar
  20. 20.
    Yoo EH, Jang JH, Park KJ, Gwak GY, Kim HJ, Kim SH, et al. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis. Int J Lab Hematol. 2011;33(5):471–6.  https://doi.org/10.1111/j.1751-553X.2011.01308.x.PubMedGoogle Scholar
  21. 21.
    Iurlo A, Cattaneo D, Gianelli U, Fermo E, Augello C, Cortelezzi A. Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis. Ann Hematol. 2015;94(5):881–2.  https://doi.org/10.1007/s00277-014-2249-z.CrossRefPubMedGoogle Scholar
  22. 22.
    Haslam K, Langabeer SE. Incidence of CALR mutations in patients with splanchnic vein thrombosis. Br J Haematol. 2015;168(3):459–60.  https://doi.org/10.1111/bjh.13121.CrossRefPubMedGoogle Scholar
  23. 23.
    Turon F, Cervantes F, Colomer D, Baiges A, Hernandez-Gea V, Garcia-Pagan JC. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. J Hepatol. 2015;62(1):72–4.  https://doi.org/10.1016/j.jhep.2014.08.032.CrossRefPubMedGoogle Scholar
  24. 24.
    • Poisson J, Plessier A, Kiladjian JJ, Turon F, Cassinat B, Andreoli A, et al. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study. J Hepatol. 2017;67(3):501–7.  https://doi.org/10.1016/j.jhep.2017.04.021. The study shows that calreticulin mutations are rare in patients with SVT CrossRefPubMedGoogle Scholar
  25. 25.
    Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113(21):5246–9.  https://doi.org/10.1182/blood-2008-11-191544.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Rosti V, Bonetti E, Bergamaschi G, Campanelli R, Guglielmelli P, Maestri M, et al. High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. PLoS One. 2010;5(12):e15277.  https://doi.org/10.1371/journal.pone.0015277.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Villani L, Bergamaschi G, Primignani M, Rosti V, Carolei A, Poletto V, et al. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. Leuk Res. 2012;36(1):e7–9.  https://doi.org/10.1016/j.leukres.2011.08.008.CrossRefPubMedGoogle Scholar
  28. 28.
    Smalberg JH, Koehler E, Darwish Murad S, Plessier A, Seijo S, Trebicka J, et al. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood. 2011;117(15):3968–73.  https://doi.org/10.1182/blood-2010-11-319087.CrossRefPubMedGoogle Scholar
  29. 29.
    Colaizzo D, Tiscia GL, Bafunno V, Amitrano L, Vergura P, Lupone MR, et al. Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis. Thromb Res. 2011;128(3):233–6.  https://doi.org/10.1016/j.thromres.2011.03.024.CrossRefPubMedGoogle Scholar
  30. 30.
    Gianelli U, Iurlo A, Cattaneo D, Bossi A, Cortinovis I, Augello C, et al. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. Leuk Res. 2015;39(5):525–9.  https://doi.org/10.1016/j.leukres.2015.03.009.CrossRefPubMedGoogle Scholar
  31. 31.
    •• De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larran A, Iurlo A, et al. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J. 2016;6(11):e493.  https://doi.org/10.1038/bcj.2016.103. Large retrsopective study of MPN-SVT shows a lower recurrence of thrombosis in anticoagulated patients. Higher recurrence was associated with BCS, splenomegaly, and leukocytosis CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Riva N, Ageno W, Poli D, Testa S, Rupoli S, Santoro R, et al. Recurrent thrombotic events after discontinuation of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter retrospective cohort study. Gastroenterol Res Pract. 2015;2015:620217.  https://doi.org/10.1155/2015/620217.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Lavu S, Szuber N, Mudireddy M, Yogarajah M, Gangat N, Pardanani A, et al. Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: the Mayo clinic experience with 84 consecutive cases. Am J Hematol. 2018;93(3):E61–E4.  https://doi.org/10.1002/ajh.24993.CrossRefPubMedGoogle Scholar
  34. 34.
    Amarapurkar P, Parekh S, Amarapurkar A, Amarapurkar D. Portal hypertension and ascites in extramedullary hematopoiesis. J Clin Exp Hepatol. 2012;2(2):188–90.  https://doi.org/10.1016/S0973-6883(12)60107-8.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Vahabzadeh B, Crippin JS. Image of the month. Portal hypertension as a result of extramedullary hematopoiesis caused by idiopathic myelofibrosis. Clin Gastroenterol Hepatol. 2008;6(4):e22.  https://doi.org/10.1016/j.cgh.2008.01.008.CrossRefPubMedGoogle Scholar
  36. 36.
    Kreher S, Ochsenreither S, Trappe RU, Pabinger I, Bergmann F, Petrides PE, et al. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol. 2014;93(12):1953–63.  https://doi.org/10.1007/s00277-014-2224-8.CrossRefPubMedGoogle Scholar
  37. 37.
    Ellis MH, Lavi N, Vannucchi A, Harrison C. Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey. Thromb Res. 2014;134(2):251–4.  https://doi.org/10.1016/j.thromres.2014.04.032.CrossRefPubMedGoogle Scholar
  38. 38.
    Spaander MC, Hoekstra J, Hansen BE, Van Buuren HR, Leebeek FW, Janssen HL. Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost. 2013;11(3):452–9.  https://doi.org/10.1111/jth.12121.CrossRefPubMedGoogle Scholar
  39. 39.
    • Potthoff A, Attia D, Pischke S, Mederacke I, Beutel G, Rifai K, et al. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. Liver Int. 2015;35(8):2042–9.  https://doi.org/10.1111/liv.12816. Retrospective study of long-term outcomes of patients who received liver transplant for Budd-Chiari due to MPN showed that there was no difference in outcomes in MPN patients compared to those without MPN. This study highlights that MPN patients are able to undergo liver transplant if needed and that liver transplant does not hasten the natural course of MPN CrossRefPubMedGoogle Scholar
  40. 40.
    Janczak DT, Mimier MK, McBane RD, Kamath PS, Simmons BS, Bott-Kitslaar DM, et al. Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location. Mayo Clin Proc. 2018;93(1):40–7.  https://doi.org/10.1016/j.mayocp.2017.10.007.CrossRefPubMedGoogle Scholar
  41. 41.
    Ianotto JC, Couturier MA, Galinat H, Mottier D, Berthou C, Guillerm G, et al. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol. 2017;106(4):517–21.  https://doi.org/10.1007/s12185-017-2282-5.CrossRefPubMedGoogle Scholar
  42. 42.
    •• Reilly CR, Babushok DV, Martin K, Spivak JL, Streiff M, Bahirwani R, et al. Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension. Am J Hematol. 2017;92(9):909–14.  https://doi.org/10.1002/ajh.24798. Multicenter retrospective analysis of patients with MPN-associated portal hypertension who received TIPs intervention shows that TIPS is an effective treatment in this entity CrossRefPubMedGoogle Scholar
  43. 43.
    Mo A, Testro A, French J, Robertson M, Angus P, Grigg A. Early radiological intervention and haematology screening is associated with excellent outcomes in Budd-Chiari syndrome. Intern Med J. 2017;47(12):1361–7.  https://doi.org/10.1111/imj.13544.CrossRefPubMedGoogle Scholar
  44. 44.
    •• Pieri L, Paoli C, Arena U, Marra F, Mori F, Zucchini M, et al. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Am J Hematol. 2017;92(2):187–95.  https://doi.org/10.1002/ajh.24614. Phase 2 clinical trial that shows ruxolitnib is safe in patients with MPN-SVT and it also reduces spleen size and spleen stiffness. Decrease in spleen /liver stiffness is typically associated with improved pHTN in patients with cirrhosis CrossRefPubMedGoogle Scholar
  45. 45.
    Coskun ME, Height S, Dhawan A, Hadzic N. Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome. BMJ Case Rep. 2017;2017:637–9.  https://doi.org/10.1136/bcr-2017-220377.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Department of MedicineNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Division of Hematology/Oncology, Department of MedicineNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations